PUBLIC COMPANY
save$GPCRStructure Therapeutics Inc.
$GPCR50.52-6.67%South San Francisco, CA, USupdated 6h ago
community read0 votes
pipeline
1
marketed
0
phase 3
0
catalysts ytd
2
approvals ytd
0
recalls ytd
0
Pipeline(1)
pipeline depth1 products
1Phase 2
Upcoming
Recent(90d)
nothing in the last 90 days
view all catalysts →Insider activity
source: SEC Form 4open-market buys + sells
routine RSU / option mechanics (6)
- Apr 15, 26grantLang Matthew · COO & GC223,776 sh
- Apr 15, 26grantLang Matthew · COO & GC184,614 sh
- Mar 19, 26grantColl Crespo Blas · CHIEF MEDICAL OFFICER93,984 sh
- Mar 19, 26grantMa Yingli · CHIEF TECHNOLOGY OFFICER32,526 sh
- Mar 19, 26grantMa Yingli · CHIEF TECHNOLOGY OFFICER40,278 sh
- Mar 19, 26grantLin Xichen · CHIEF SCIENTIFIC OFFICER43,368 sh
🐶 Hiring Signal
next earnings Nov 5, 2026
News
- Novo takes first round of oral obesity duel. Can it stay ahead of Lilly?Despite coming away with an early victory over Eli Lilly in the oral obesity face-off, analysts don’t expect Novo Nordisk’s lead to last for very long.biospace · 1d ago
- AstraZeneca pulls plug on late-stage lung cancer trial, taking another clinical blowAstraZeneca will push through with its other Phase 3 studies for volrustomig, including in cervical cancer and mesothelioma.biospace · 3d ago
- AstraZeneca pulls plug on late-stage lung cancer trial, taking another clinical blowAstraZeneca will push through with its other Phase 3 studies for volrustomig, including in cervical cancer and mesothelioma.biospace · 3d ago
- #ADA26: AstraZeneca's GLP-1 pill cuts weight by 10.5% after six monthsThe race to be third to market with an obesity pill has a number of contenders, including Roche, Pfizer and Structure Therapeutics. On Monday, AstraZeneca set out its own stall with data on a pill ...endpoints · 2mo ago
Data sources
last refreshed 15m ago
Found something off?
comments(0)
5-min edit window · permanent after that